Genetic Disorders Drug Market Report

Global Genetic Disorders Drug Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Feb 25, 2022
  • PAGES：229
  • REPORT CODE：GMM776580
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Genetic Disorders Drug market report explains the definition, types, applications, major countries, and major players of the Genetic Disorders Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Vertex

    • Sanofi

    • Sarepta

    • BioMarin

    • Pfizer

    • Amgen

    • GW Pharmaceuticals

    • Shire

    By Type:

    • Cystic Fibrosis (CF)

    • Duchenne Muscular Dystrophy (DMD)

    • Lysosomal Storage Disease (LSD)

    • Paroxysmal Nocturnal Hemoglobinuria (PNH)

    By End-User:

    • Clinic

    • Hospital

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Genetic Disorders Drug Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Genetic Disorders Drug Outlook to 2028- Original Forecasts

    • 2.2 Genetic Disorders Drug Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Genetic Disorders Drug Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Genetic Disorders Drug Market- Recent Developments

    • 6.1 Genetic Disorders Drug Market News and Developments

    • 6.2 Genetic Disorders Drug Market Deals Landscape

    7 Genetic Disorders Drug Raw Materials and Cost Structure Analysis

    • 7.1 Genetic Disorders Drug Key Raw Materials

    • 7.2 Genetic Disorders Drug Price Trend of Key Raw Materials

    • 7.3 Genetic Disorders Drug Key Suppliers of Raw Materials

    • 7.4 Genetic Disorders Drug Market Concentration Rate of Raw Materials

    • 7.5 Genetic Disorders Drug Cost Structure Analysis

      • 7.5.1 Genetic Disorders Drug Raw Materials Analysis

      • 7.5.2 Genetic Disorders Drug Labor Cost Analysis

      • 7.5.3 Genetic Disorders Drug Manufacturing Expenses Analysis

    8 Global Genetic Disorders Drug Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Genetic Disorders Drug Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Genetic Disorders Drug Export by Region (Top 10 Countries) (2017-2028)

    9 Global Genetic Disorders Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Genetic Disorders Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Cystic Fibrosis (CF) Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Duchenne Muscular Dystrophy (DMD) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Lysosomal Storage Disease (LSD) Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Consumption and Growth Rate (2017-2022)

    • 9.2 Global Genetic Disorders Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Genetic Disorders Drug Market Analysis and Outlook till 2022

    • 10.1 Global Genetic Disorders Drug Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Genetic Disorders Drug Consumption (2017-2022)

      • 10.2.2 Canada Genetic Disorders Drug Consumption (2017-2022)

      • 10.2.3 Mexico Genetic Disorders Drug Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.2 UK Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.3 Spain Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.4 Belgium Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.5 France Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.6 Italy Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.7 Denmark Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.8 Finland Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.9 Norway Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.10 Sweden Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.11 Poland Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.12 Russia Genetic Disorders Drug Consumption (2017-2022)

      • 10.3.13 Turkey Genetic Disorders Drug Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.2 Japan Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.3 India Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.4 South Korea Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.5 Pakistan Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.6 Bangladesh Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.7 Indonesia Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.8 Thailand Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.9 Singapore Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.10 Malaysia Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.11 Philippines Genetic Disorders Drug Consumption (2017-2022)

      • 10.4.12 Vietnam Genetic Disorders Drug Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.2 Colombia Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.3 Chile Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.4 Argentina Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.5 Venezuela Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.6 Peru Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.7 Puerto Rico Genetic Disorders Drug Consumption (2017-2022)

      • 10.5.8 Ecuador Genetic Disorders Drug Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Genetic Disorders Drug Consumption (2017-2022)

      • 10.6.2 Kuwait Genetic Disorders Drug Consumption (2017-2022)

      • 10.6.3 Oman Genetic Disorders Drug Consumption (2017-2022)

      • 10.6.4 Qatar Genetic Disorders Drug Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Genetic Disorders Drug Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Genetic Disorders Drug Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Genetic Disorders Drug Consumption (2017-2022)

      • 10.7.2 South Africa Genetic Disorders Drug Consumption (2017-2022)

      • 10.7.3 Egypt Genetic Disorders Drug Consumption (2017-2022)

      • 10.7.4 Algeria Genetic Disorders Drug Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Genetic Disorders Drug Consumption (2017-2022)

      • 10.8.2 New Zealand Genetic Disorders Drug Consumption (2017-2022)

    11 Global Genetic Disorders Drug Competitive Analysis

    • 11.1 Vertex

      • 11.1.1 Vertex Company Details

      • 11.1.2 Vertex Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Vertex Genetic Disorders Drug Main Business and Markets Served

      • 11.1.4 Vertex Genetic Disorders Drug Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Sanofi

      • 11.2.1 Sanofi Company Details

      • 11.2.2 Sanofi Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Sanofi Genetic Disorders Drug Main Business and Markets Served

      • 11.2.4 Sanofi Genetic Disorders Drug Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Sarepta

      • 11.3.1 Sarepta Company Details

      • 11.3.2 Sarepta Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Sarepta Genetic Disorders Drug Main Business and Markets Served

      • 11.3.4 Sarepta Genetic Disorders Drug Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 BioMarin

      • 11.4.1 BioMarin Company Details

      • 11.4.2 BioMarin Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 BioMarin Genetic Disorders Drug Main Business and Markets Served

      • 11.4.4 BioMarin Genetic Disorders Drug Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Pfizer

      • 11.5.1 Pfizer Company Details

      • 11.5.2 Pfizer Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Pfizer Genetic Disorders Drug Main Business and Markets Served

      • 11.5.4 Pfizer Genetic Disorders Drug Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Amgen

      • 11.6.1 Amgen Company Details

      • 11.6.2 Amgen Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Amgen Genetic Disorders Drug Main Business and Markets Served

      • 11.6.4 Amgen Genetic Disorders Drug Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 GW Pharmaceuticals

      • 11.7.1 GW Pharmaceuticals Company Details

      • 11.7.2 GW Pharmaceuticals Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 GW Pharmaceuticals Genetic Disorders Drug Main Business and Markets Served

      • 11.7.4 GW Pharmaceuticals Genetic Disorders Drug Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Shire

      • 11.8.1 Shire Company Details

      • 11.8.2 Shire Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Shire Genetic Disorders Drug Main Business and Markets Served

      • 11.8.4 Shire Genetic Disorders Drug Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    12 Global Genetic Disorders Drug Market Outlook by Types and Applications to 2028

    • 12.1 Global Genetic Disorders Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Cystic Fibrosis (CF) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Duchenne Muscular Dystrophy (DMD) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Lysosomal Storage Disease (LSD) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Genetic Disorders Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Genetic Disorders Drug Market Analysis and Outlook to 2028

    • 13.1 Global Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.2.2 Canada Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.2 UK Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.3 Spain Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.5 France Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.6 Italy Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.8 Finland Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.9 Norway Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.11 Poland Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.12 Russia Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.2 Japan Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.3 India Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.3 Chile Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.6 Peru Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.6.3 Oman Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Genetic Disorders Drug Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Genetic Disorders Drug Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Genetic Disorders Drug Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Genetic Disorders Drug

    • Figure of Genetic Disorders Drug Picture

    • Table Global Genetic Disorders Drug Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Genetic Disorders Drug Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Cystic Fibrosis (CF) Consumption and Growth Rate (2017-2022)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Consumption and Growth Rate (2017-2022)

    • Figure Global Lysosomal Storage Disease (LSD) Consumption and Growth Rate (2017-2022)

    • Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Genetic Disorders Drug Consumption by Country (2017-2022)

    • Table North America Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure United States Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Canada Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Mexico Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure Germany Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure UK Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Spain Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Belgium Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure France Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Italy Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Denmark Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Finland Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Norway Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Sweden Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Poland Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Russia Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Turkey Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table APAC Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure China Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure India Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Thailand Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Singapore Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Philippines Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table South America Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure Brazil Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Colombia Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Chile Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Argentina Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Peru Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table GCC Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure Bahrain Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Oman Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Qatar Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table Africa Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure Nigeria Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure South Africa Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Egypt Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure Algeria Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table Oceania Genetic Disorders Drug Consumption by Country (2017-2022)

    • Figure Australia Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Genetic Disorders Drug Consumption and Growth Rate (2017-2022)

    • Table Vertex Company Details

    • Table Vertex Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Vertex Genetic Disorders Drug Main Business and Markets Served

    • Table Vertex Genetic Disorders Drug Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Genetic Disorders Drug Main Business and Markets Served

    • Table Sanofi Genetic Disorders Drug Product Portfolio

    • Table Sarepta Company Details

    • Table Sarepta Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sarepta Genetic Disorders Drug Main Business and Markets Served

    • Table Sarepta Genetic Disorders Drug Product Portfolio

    • Table BioMarin Company Details

    • Table BioMarin Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table BioMarin Genetic Disorders Drug Main Business and Markets Served

    • Table BioMarin Genetic Disorders Drug Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Genetic Disorders Drug Main Business and Markets Served

    • Table Pfizer Genetic Disorders Drug Product Portfolio

    • Table Amgen Company Details

    • Table Amgen Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Genetic Disorders Drug Main Business and Markets Served

    • Table Amgen Genetic Disorders Drug Product Portfolio

    • Table GW Pharmaceuticals Company Details

    • Table GW Pharmaceuticals Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table GW Pharmaceuticals Genetic Disorders Drug Main Business and Markets Served

    • Table GW Pharmaceuticals Genetic Disorders Drug Product Portfolio

    • Table Shire Company Details

    • Table Shire Genetic Disorders Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shire Genetic Disorders Drug Main Business and Markets Served

    • Table Shire Genetic Disorders Drug Product Portfolio

    • Figure Global Cystic Fibrosis (CF) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lysosomal Storage Disease (LSD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Table North America Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure Germany Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure China Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure Brazil Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Genetic Disorders Drug Consumption Forecast by Country (2022-2028)

    • Figure Australia Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Genetic Disorders Drug Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US